Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

BMS

    • Home
    • BMS
    • Page 9
Company Deals

Baheal Partners with AstraZeneca for Commercial Rights to Onglyza

Fineline Cube Nov 11, 2022

China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca...

Company Legal / IP R&D

Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief

Fineline Cube Aug 8, 2022

China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as...

Company Drug

Bristol-Myers Squibb Launches Reblozyl in China for β-Thalassemia Treatment

Fineline Cube Jun 15, 2022

US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the commercial launch of its...

Posts pagination

1 … 8 9

Recent updates

  • Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint
  • Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures
  • Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes
  • Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod
  • TransThera Tinengotinib Cholangiocarcinoma Priority Review China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.